NCT00556530 Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome
| NCT ID | NCT00556530 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Albert Einstein College of Medicine |
| Condition | DiGeorge Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2016-07 |
| Primary Completion | 2029-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2016-07 with a primary completion date of 2029-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
22q11.2 deletion syndrome is a genetic disorder that can cause heart defects, facial abnormalities, and developmental and learning disabilities. The severity of the disorder can vary widely among people. This study will analyze DNA from people with 22q11.2 deletion syndrome to identify genetic variations that may affect the severity of the disorder.
Eligibility Criteria
Inclusion Criteria: * Has 22q11 deletion of 3 megabases (Mb) Exclusion Criteria: * Has 22q11 deletion smaller than 3 Mb or no deletion
Contact & Investigator
Bernice E. Morrow, PhD
PRINCIPAL INVESTIGATOR
Albert Einstein College of Medicine
Frequently Asked Questions
Who can join the NCT00556530 clinical trial?
This trial is open to participants of all sexes, studying DiGeorge Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00556530 currently recruiting?
Yes, NCT00556530 is actively recruiting participants. Contact the research team at bernice.morrow@einsteinmed.edu for enrollment information.
Where is the NCT00556530 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT00556530 clinical trial?
NCT00556530 is sponsored by Albert Einstein College of Medicine. The principal investigator is Bernice E. Morrow, PhD at Albert Einstein College of Medicine. The trial plans to enroll 1,000 participants.